Francisco Casquero Ocio-rekin lankidetzan egindako argitalpenak (8)

2021

  1. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: Toxicity, prostatespecific antigen kinetics, and cancer control

    Journal of Contemporary Brachytherapy, Vol. 13, Núm. 1, pp. 12-17

2020

  1. MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?

    Clinical and Translational Radiation Oncology, Vol. 24, pp. 135-139

  2. Pain response and quality of life assessment in patients with moderate/severe neuropathic pain due to bone metastasis undergoing treatment with palliative radiotherapy and tapentadol: A prospective multicentre pilot study

    Journal of Medical Imaging and Radiation Oncology, Vol. 64, Núm. 6, pp. 859-865

  3. Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial

    Radiotherapy and Oncology, Vol. 146, pp. 16-20

2019

  1. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study

    Radiotherapy and Oncology, Vol. 135, pp. 13-18

2018

  1. Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial

    Radiotherapy and Oncology, Vol. 126, Núm. 2, pp. 278-282

  2. Pretreatment Multiparametric Magnetic Resonance Imaging Findings Are More Accurate Independent Predictors of Outcome Than Clinical Variables in Localized Prostate Cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 101, Núm. 5, pp. 1172-1178

2016

  1. Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy

    Journal of Contemporary Brachytherapy, Vol. 8, Núm. 6, pp. 477-483